Bris­tol My­ers inks pro­tein de­grad­er deal via Cel­gene team's link to seed-stage biotech

Bris­tol My­ers Squibb is adding to its pro­tein de­grad­er line­up, which al­ready in­cludes the likes of A-Al­pha Bio and Evotec, by link­ing arms with a lit­tle-known biotech that’s been com­mu­ni­cat­ing with the sci­en­tists at Cel­gene for the past few years.

The Big Phar­ma is in­vest­ing in Syn­theX and lay­ing out a $550 mil­lion vi­sion for the Bay Area seed-stage biotech that was just “a sketch on a nap­kin” in Toron­to in 2016, co-founder and CEO Maria Solov­ey­chik told End­points News in a pre­view of the Tues­day morn­ing pact.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.